Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis

Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus

Petri, M., Orbai, A., Alarcón, G. S., Gordon, C., Merrill, J. T., Fortin, P. R., Bruce, I. N., Isenberg, D., Wallace, D. J., Nived, O., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34473 · Cited by 5,322 · see citing works

Systemic Lupus Erythematosus

Rahman, A., & Isenberg, D. A. (2008) · New England Journal of Medicine · doi:10.1056/nejmra071297 · Cited by 1,633 · see citing works

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

Goede, V., Fischer, K., Busch, R. M., Engelke, A., Eichhorst, B. F., Wendtner, C., Chagorova, T., de la Serna, J., Dilhuydy, M., Illmer, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313984 · Cited by 1,522 · see citing works

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study

Rovin, B. H., Furie, R. A., Latinis, K. M., Looney, R. J., Fervenza, F. C., Sánchez‐Guerrero, J., Maciuca, R. D., Zhang, D., Garg, J. P., Brunetta, P. G., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34359 · Cited by 1,467 · see citing works

Efficacy and safety of rituximab in moderately‐to‐severely active systemic lupus erythematosus: The randomized, double‐blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial

Merrill, J. T., Neuwelt, C. M., Wallace, D. J., Shanahan, J. C., Latinis, K. M., Oates, J. C., Utset, T. O., Gordon, C., Isenberg, D. A., Hsieh, H., et al. (2009) · Arthritis & Rheumatism · doi:10.1002/art.27233 · Cited by 1,414 · see citing works

New insights into the immunopathogenesis of systemic lupus erythematosus

Tsokos, G. C., Lo, M. S., Costa‐Reis, P., & Sullivan, K. E. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.186 · Cited by 1,225 · see citing works

Systemic Lupus Erythematosus

Rahman, M. U. (2008) · Elsevier eBooks · doi:10.1016/b978-1-4160-4007-1.50153-x · Cited by 1,022 · see citing works

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicity

Mössner, E., Brünker, P., Moser, S., Püntener, U., Schmidt, C., Herter, S., Grau, R., Gerdes, C. A., Nopora, A., van Puijenbroek, E., et al. (2010) · Blood · doi:10.1182/blood-2009-06-225979 · Cited by 983 · see citing works

B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose‐escalation trial of rituximab

Looney, R. J., Anolik, J. H., Campbell, D., Felgar, R. E., Young, F. M., Arend, L. J., Sloand, J. A., Rosenblatt, J. D., & Sanz, I. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20430 · Cited by 779 · see citing works

Excess BAFF Rescues Self-Reactive B Cells from Peripheral Deletion and Allows Them to Enter Forbidden Follicular and Marginal Zone Niches

Thien, M., Phan, T. G., Gardam, S., Amesbury, M., Basten, A., Mackay, F., & Brink, R. A. (2004) · Immunity · doi:10.1016/j.immuni.2004.05.010 · Cited by 745 · see citing works

The Innate Mononuclear Phagocyte Network Depletes B Lymphocytes through Fc Receptor–dependent Mechanisms during Anti-CD20 Antibody Immunotherapy

Uchida, J., Hamaguchi, Y., Oliver, J. A., Ravetch, J. V., Poe, J. C., Haas, K. M., & Tedder, T. F. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040119 · Cited by 636 · see citing works

Systemic lupus erythematosus

Manson, J. J., & Rahman, A. (2006) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-1-6 · Cited by 607 · see citing works

An open study of B lymphocyte depletion in systemic lupus erythematosus

Leandro, M. J., Edwards, J., Cambridge, G., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10541 · Cited by 577 · see citing works

Importance of Cellular Microenvironment and Circulatory Dynamics in B Cell Immunotherapy

Gong, Q., Ou, Q., Ye, S., Lee, W. P., Cornelius, J., Diehl, L. J., Lin, W. Y., Hu, Z., Lu, Y., Chen, Y., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.2.817 · Cited by 542 · see citing works

B CELL IMMUNOBIOLOGY IN DISEASE: Evolving Concepts from the Clinic

Martin, F., & Chan, A. C. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090517 · Cited by 365 · see citing works

In Situ B Cell-Mediated Immune Responses and Tubulointerstitial Inflammation in Human Lupus Nephritis

Chang, A., Henderson, S., Brandt, D. R., Liu, N., Guttikonda, R., Hsieh, C., Kaverina, N., Utset, T. O., Meehan, S. M., Quigg, R. J., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1001983 · Cited by 361 · see citing works

Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus nephritis cohort

Dall'Era, M., Cisternas, M. G., Smilek, D. E., Straub, L., Houssiau, F. A., Cervera, R., Rovin, B. H., & Mackay, M. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39026 · Cited by 329 · see citing works

Predicting outcomes of lupus nephritis with tubulointerstitial inflammation and scarring

Hsieh, C., Chang, A., Brandt, D. R., Guttikonda, R., Utset, T. O., & Clark, M. R. (2011) · Arthritis Care & Research · doi:10.1002/acr.20441 · Cited by 323 · see citing works

Rituximab Therapy in Idiopathic Membranous Nephropathy

Fervenza, F. C., Abraham, R. S., Erickson, S. B., et al. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.05080610 · Cited by 298 · see citing works

Rituximab treatment of idiopathic membranous nephropathy

Fervenza, F. C., Cosío, B. G., Erickson, S. B., Specks, U., Herzenberg, A. M., Dillon, J. J., Leung, N., Cohen, I. M., Wochos, D. N., Bergstralh, E. J., et al. (2007) · Kidney International · doi:10.1038/sj.ki.5002628 · Cited by 264 · see citing works

B cell biomarkers of rituximab responses in systemic lupus erythematosus

Vital, E. M. J., Dass, S., Buch, M. H., et al. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30466 · Cited by 242 · see citing works

A proteinuria cut-off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial

Tamirou, F., Lauwerys, B. R., Dall’Era, M., et al. (2015) · Lupus Science & Medicine · doi:10.1136/lupus-2015-000123 · Cited by 242 · see citing works

Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide‐resistant proliferative lupus nephritis

Gunnarsson, I., Sundelin, B., Jonsdottir, T., Jacobson, S. H., Henriksson, E. W., & van Vollenhoven, R. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22505 · Cited by 241 · see citing works

Depletion of B Cells in Murine Lupus: Efficacy and Resistance

Ahuja, A., Shupe, J., Dunn, R., Kashgarian, M. J., Kehry, M. R., & Shlomchik, M. J. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.5.3351 · Cited by 239 · see citing works

Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus

Albert, D., Dunham, J., Khan, S., Stansberry, J., Kolasinski, S. L., Tsai, D., Pullman‐Mooar, S., Barnack, F., Striebich, C. C., Looney, R. J., et al. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.083162 · Cited by 209 · see citing works

Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples

Reddy, V. R., Klein, C., Isenberg, D. A., Glennie, M. J., Cambridge, G., Cragg, M. S., & Leandro, M. J. (2017) · Lara D. Veeken · doi:10.1093/rheumatology/kex067 · Cited by 205 · see citing works

Monocyte Subsets Responsible for Immunoglobulin G-Dependent Effector Functions In Vivo

Biburger, M., Aschermann, S., Schwab, I., Lux, A., Albert, H., Danzer, H., Woigk, M., Dudziak, D., & Nimmerjahn, F. (2011) · Immunity · doi:10.1016/j.immuni.2011.11.009 · Cited by 147 · see citing works

Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway

Honeychurch, J., Alduaij, W., Azizyan, M., Cheadle, E. J., Pelicano, H., Ivanov, A., Huang, P., Cragg, M. S., & Illidge, T. (2012) · Blood · doi:10.1182/blood-2011-12-395541 · Cited by 130 · see citing works

Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS)

Sinclair, A., Appel, G. B., Dooley, M. A., et al. (2007) · Lupus · doi:10.1177/0961203307084712 · Cited by 113 · see citing works

Internalization of Rituximab and the Efficiency of B Cell Depletion in Rheumatoid Arthritis and Systemic Lupus Erythematosus

Reddy, V. R., Cambridge, G., Isenberg, D. A., Glennie, M. J., Cragg, M. S., & Leandro, M. J. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39167 · Cited by 101 · see citing works

Prolonged effects of short‐term anti‐CD20 B cell depletion therapy in murine systemic lupus erythematosus

Bekar, K. W., Owen, T., Dunn, R., Ichikawa, T., Wang, W., Wang, R., Barnard, J., Brady, S. P., Nevarez, S., Goldman, B., et al. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27515 · Cited by 100 · see citing works

Clinical associations of anti-Smith antibodies in PROFILE: a multi-ethnic lupus cohort

Arroyo-Ávila, M., Santiago‐Casas, Y., McGwin, G., Cantor, R. S., Petri, M., Ramsey‐Goldman, R., Reveille, J. D., Kimberly, R. P., Alarcón, G. S., Vilá, L. M., et al. (2015) · Clinical Rheumatology · doi:10.1007/s10067-015-2941-y · Cited by 97 · see citing works

The Pathogenesis and Therapeutic Implications of Tubulointerstitial Inflammation in Human Lupus Nephritis

Clark, M. R., Trotter, K. C., & Chang, A. (2015) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2015.08.007 · Cited by 91 · see citing works

Detection and quantification of rituximab in the human urine

Jacobs, R., Langer-Jacobus, T., Duong, M., et al. (2017) · Journal of Immunological Methods · doi:10.1016/j.jim.2017.09.001 · Cited by 55 · see citing works

Understanding the mechanistic basis in rheumatoid arthritis for clinical response to anti‐CD20 therapy: the B‐cell roadblock hypothesis

Silverman, G. J., & Boyle, D. L. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00627.x · Cited by 51 · see citing works

Optimising B-cell depletion in autoimmune disease: is obinutuzumab the answer?

Reddy, V. R., Dahal, L. N., Cragg, M. S., & Leandro, M. J. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.06.009 · Cited by 51 · see citing works

An Acquired Defect in IgG-Dependent Phagocytosis Explains the Impairment in Antibody-Mediated Cellular Depletion in Lupus

Ahuja, A., Teichmann, L. L., Wang, H., Dunn, R., Kehry, M. R., & Shlomchik, M. J. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1101629 · Cited by 41 · see citing works

Anti‐Sm is associated with the early poor outcome of lupus nephritis

Ahn, S. S., Yoo, B.-W., Song, J. J., et al. (2016) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.12880 · Cited by 30 · see citing works

Serum rituximab levels and efficiency of B cell depletion: differences between patients with rheumatoid arthritis and systemic lupus erythematosus

Reddy, V. R., Croca, S. C., Gerona, D., et al. (2013) · Lara D. Veeken · doi:10.1093/rheumatology/ket004 · Cited by 28 · see citing works

Longer duration of B cell depletion is associated with better outcome

Dias, S. S., Rodriguez-Garcia, V., Nguyen, H. V., et al. (2015) · Lara D. Veeken · doi:10.1093/rheumatology/kev036 · Cited by 24 · see citing works

N-linked carbohydrates in tyrosinase are required for its recognition by human MHC class II-restricted CD4+ T cells

Housseau, F., Moorthy, A., Langer, D., Robbins, P. F., Gonzales, M. I., & Topalian, S. L. (2001) · European Journal of Immunology · doi:10.1002/1521-4141(200109)31:9 · Cited by 20 · see citing works

Kinetics of Rituximab Excretion into Urine and Peritoneal Fluid in Two Patients with Nephrotic Syndrome

Stahl, K., Duong, M., Schwarz, A., et al. (2017) · Case Reports in Nephrology · doi:10.1155/2017/1372859 · Cited by 20 · see citing works

2019 update of the EULAR recommendations for the management of systemic lupus erythematosus

Fanouriakis, A., Kostopoulou, M., Alunno, A., Aringer, M., Bajema, I., Boletis, J. N., Cervera, R., Doria, A., Gordon, C., Govoni, M., et al. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-215089 · Cited by 2,011 · see citing works

Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: Review of the literature and personalized risk-based prevention strategy

Haanen, J., Ernstoff, M. S., Wang, Y., Menzies, A. M., Puzanov, I., Grivas, P., Larkin, J., Peters, S., Thompson, J. A., & Obeid, M. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.285 · Cited by 222 · see citing works

效果热门在有干燥眼睛疾病的病人的角膜的内皮细胞层上的 0.05% cyclosporine A

Consuelo, Pérez-Rico, Francisco, et al. (2013) · Acta Scientiarum Naturalium Universitatis Sunyatseni

[Rituximab for managing refractory thrombotic thrombocytopenic purpura: a report of three cases].

Yamanouchi, J., Hato, T., Miyoshi, K., et al. (2013) · PubMed

Anti-Rituximab antibody in patients with NMOSDs treated with low dose Rituximab

Li, T., Zhang, L., Zhang, Q., Yang, C., Zhang, C., Li, Y.-J., Shi, F., & Li, Y. (2017) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2017.12.021 · Cited by 35 · see citing works

Hemoglobin Levels Across the Pediatric Critical Care Spectrum: A Point Prevalence Study*

Hassan, N. E., Reischman, D. E., Fitzgerald, R. K., & Faustino, E. V. S. (2018) · Pediatric Critical Care Medicine · doi:10.1097/pcc.0000000000001467 · Cited by 8 · see citing works

Prognostic value of proadrenomedullin in patients with COVID-19 pneumonia

Astapovskii, A. A., Drozdov, V. N., Ших, Е. В., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.961071 · Cited by 4 · see citing works